Leonard Florence Center For Living | |
165 Captain's Row, Chelsea, Massachusetts 02150 | |
(617) 887-0001 | |
Name | Leonard Florence Center For Living |
---|---|
Location | 165 Captain's Row, Chelsea, Massachusetts |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 100 |
Occupancy Rate | 88.6% |
Medicare ID (CCN) | 225775 |
Legal Business Name | Chelsea Jewish Green House, Inc. |
Ownership Type | Non Profit - Corporation |
NPI Number | 1336411727 |
Organization Name | CHELSEA JEWISH GREEN HOUSE |
Doing Business As | LEONARD FLORENCE CENTER FOR LIVING |
Address | 165 Captains Row, Chelsea, MA 02150 |
Phone Number | 617-887-0001 |
News Archive
Acura Pharmaceuticals, Inc. today reported a second quarter 2010 net loss of $3.2 million or $0.07 per share compared to net loss of $6.5 million, or $0.14 per share for the second quarter of 2009. For the six months ended June 30, 2010, the Company reported a net loss of $7.2 million, or $0.15 per share compared to net loss of $7.8 million, or $0.17 per share for the same period in 2009. At July 29, 2010 we had cash and cash equivalents of approximately $26.5 million with no term indebtedness.
In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care.
An individualized diet based on a person's genetics, microbiome and lifestyle is more effective in controlling blood glucose (sugar) levels than one that considers only nutritional composition of food, Mayo Clinic researchers have confirmed.
Glioblastoma brain tumors can have an unusual effect on the body's immune system, often causing a dramatic drop in the number of circulating T-cells that help drive the body's defenses.
In a novel animal study design that mimicked human clinical trials, researchers at University of California, San Diego School of Medicine report that long-term treatment using a small molecule drug that reduces activity of the brain's stress circuitry significantly reduces Alzheimer's disease (AD) neuropathology and prevents onset of cognitive impairment in a mouse model of the neurodegenerative condition.
› Verified 7 days ago
NPI Number | 1689806937 |
Organization Name | CHELSEA JEWISH GREEN HOUSE, INC |
Doing Business As | LEONARD FLORENCE CENTER FOR LIVING |
Address | 165 Captains Row, Chelsea, MA 02150 |
Phone Number | 617-887-0001 |
News Archive
Acura Pharmaceuticals, Inc. today reported a second quarter 2010 net loss of $3.2 million or $0.07 per share compared to net loss of $6.5 million, or $0.14 per share for the second quarter of 2009. For the six months ended June 30, 2010, the Company reported a net loss of $7.2 million, or $0.15 per share compared to net loss of $7.8 million, or $0.17 per share for the same period in 2009. At July 29, 2010 we had cash and cash equivalents of approximately $26.5 million with no term indebtedness.
In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care.
An individualized diet based on a person's genetics, microbiome and lifestyle is more effective in controlling blood glucose (sugar) levels than one that considers only nutritional composition of food, Mayo Clinic researchers have confirmed.
Glioblastoma brain tumors can have an unusual effect on the body's immune system, often causing a dramatic drop in the number of circulating T-cells that help drive the body's defenses.
In a novel animal study design that mimicked human clinical trials, researchers at University of California, San Diego School of Medicine report that long-term treatment using a small molecule drug that reduces activity of the brain's stress circuitry significantly reduces Alzheimer's disease (AD) neuropathology and prevents onset of cognitive impairment in a mouse model of the neurodegenerative condition.
› Verified 7 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Acura Pharmaceuticals, Inc. today reported a second quarter 2010 net loss of $3.2 million or $0.07 per share compared to net loss of $6.5 million, or $0.14 per share for the second quarter of 2009. For the six months ended June 30, 2010, the Company reported a net loss of $7.2 million, or $0.15 per share compared to net loss of $7.8 million, or $0.17 per share for the same period in 2009. At July 29, 2010 we had cash and cash equivalents of approximately $26.5 million with no term indebtedness.
In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care.
An individualized diet based on a person's genetics, microbiome and lifestyle is more effective in controlling blood glucose (sugar) levels than one that considers only nutritional composition of food, Mayo Clinic researchers have confirmed.
Glioblastoma brain tumors can have an unusual effect on the body's immune system, often causing a dramatic drop in the number of circulating T-cells that help drive the body's defenses.
In a novel animal study design that mimicked human clinical trials, researchers at University of California, San Diego School of Medicine report that long-term treatment using a small molecule drug that reduces activity of the brain's stress circuitry significantly reduces Alzheimer's disease (AD) neuropathology and prevents onset of cognitive impairment in a mouse model of the neurodegenerative condition.
› Verified 7 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 4.23 | 14.46 |
Percentage of long-stay residents who lose too much weight | 8.33 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 55.77 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.4 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 0.39 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0.77 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 2.9 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 90.22 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 13.06 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 98.67 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0.81 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 12.66 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 27.2 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 10.67 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.3 | 95.98 |
Percentage of short-stay residents who made improvements in function | 90.51 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 98.59 | 82.93 |
News Archive
Acura Pharmaceuticals, Inc. today reported a second quarter 2010 net loss of $3.2 million or $0.07 per share compared to net loss of $6.5 million, or $0.14 per share for the second quarter of 2009. For the six months ended June 30, 2010, the Company reported a net loss of $7.2 million, or $0.15 per share compared to net loss of $7.8 million, or $0.17 per share for the same period in 2009. At July 29, 2010 we had cash and cash equivalents of approximately $26.5 million with no term indebtedness.
In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care.
An individualized diet based on a person's genetics, microbiome and lifestyle is more effective in controlling blood glucose (sugar) levels than one that considers only nutritional composition of food, Mayo Clinic researchers have confirmed.
Glioblastoma brain tumors can have an unusual effect on the body's immune system, often causing a dramatic drop in the number of circulating T-cells that help drive the body's defenses.
In a novel animal study design that mimicked human clinical trials, researchers at University of California, San Diego School of Medicine report that long-term treatment using a small molecule drug that reduces activity of the brain's stress circuitry significantly reduces Alzheimer's disease (AD) neuropathology and prevents onset of cognitive impairment in a mouse model of the neurodegenerative condition.
› Verified 7 days ago
Soldiers Home In Massachusetts Location: 91 Crest Avenue, Chelsea, Massachusetts 02150 Phone: (617) 884-5660 | |
Katzman Family Center For Living Location: 17 Lafayette Avenue, Chelsea, Massachusetts 02150 Phone: (617) 884-6766 | |
Eastpointe Rehab Center Location: 255 Central Avenue, Chelsea, Massachusetts 02150 Phone: (617) 884-5700 | |
Leonard Florence Center For Living Location: 165 Captain's Row, Chelsea, Massachusetts 02150 Phone: (617) 887-0001 |